{
  "docId": "019de073-7e4e-7689-a01c-e0840dac2b61",
  "docSlug": "97e34d6c4db7d9454440fee3efd43545",
  "documentTitle": "Axcella Health | Results Presentation Deck | 62 slides",
  "authorId": "axcella-health",
  "authorName": "Axcella Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 46,
  "pageCount": 62,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 54,
  "notes": "N=931. Data presented for Placebo, OCA 10mg, and OCA 25mg cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7e4e-7689-a01c-e0840dac2b61/46",
  "deckHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61",
  "deckJsonHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61.json",
  "deckAnchorHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "chart",
      "text": "ELF score mean change from baseline by time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2735facc-4fae-4651-99da-f96e08fc7caa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.35,
        "y": 0.7
      },
      "kind": "list",
      "text": "Patients with >1-stage fibrosis improvement had the greatest improvement in NITs, while patients with >1-stage fibrosis worsening typically showed no NIT improvement. AUROC values for each of these were suggestive of only weak association. NIT improvements observed in REGENERATE are associated with fibrosis improvement at Month 18, individual NIT changes are not likely to be effective univariate clinical predictors of fibrosis improvement by Month 18.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfea50a4-9d9c-419e-ac0c-49f3c65eeb20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "ELF Monitoring Response to Therapeutic Interventions",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "222ffe5a-b711-4337-82e8-cf7d4255fc31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Rinella ME. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 Mar;76(3):536-548",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6483c869-5074-4ca7-906b-5b546744edba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.34,
        "y": 0.1
      },
      "kind": "title",
      "text": "EVIDENCE FROM REGENERATE TRIAL 18-MONTH INTERIM ANALYSIS – OBETICHOLIC ACID",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a03ec74c-4416-40e7-8ccd-ba42da5aea88",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}